Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9BUV8

UPID:
RCAF1_HUMAN

ALTERNATIVE NAMES:
Obligate partner of TMCO1 insertase; Rab5-interacting protein; Respirasome Complex Assembly Factor 1

ALTERNATIVE UPACC:
Q9BUV8; E1P5U0; O00605; Q5QPG6; Q5QPG7; Q9BT03; Q9BZU7; Q9UI05

BACKGROUND:
The protein GEL complex subunit OPTI, known for its involvement in the insertion of multi-pass membrane proteins and assembly of mitochondrial respiratory complexes, is essential for proper cellular function. Its alternative names include Obligate partner of TMCO1 insertase and Rab5-interacting protein. The protein's role in the MPT complex and its interaction with the SEC61 complex underscore its critical function in membrane protein insertion and mitochondrial function.

THERAPEUTIC SIGNIFICANCE:
Linked to a rare autosomal recessive disorder characterized by craniofacial, skeletal, and intellectual anomalies, GEL complex subunit OPTI's dysfunction highlights its potential as a therapeutic target. Understanding the role of GEL complex subunit OPTI could open doors to potential therapeutic strategies, emphasizing the importance of research in this area for developing novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.